Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant

Transplantation

Volumn 82, Issue 1, 2006, Pages 55-61

  Pascual, Julio ^a   Van Hooff, Johannes P ^b   Salmela, Kaija ^c   Lang, Philippe ^d   Rigotti, Paolo ^e   Budde, Klemens ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITY OF PADOVA   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

3 year follow up; Immunosuppression minimization; Tacrolimus

Indexed keywords

INSULIN; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTHROPATHY; ARTICLE; BONE DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG WITHDRAWAL; FOLLOW UP; FRACTURE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECT; FEMALE; GRAFT REJECTION; MALE; METHODOLOGY; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; STEROIDS; TACROLIMUS; TREATMENT OUTCOME;

EID: 33747476104     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000225806.80890.5e     Document Type: Article

References (20)

1. Baboolal K, Jones GA, Janezic A, et al. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61(2): 686.
2. Jindal RM, Hariharan S. Chronic rejection in kidney transplants. An in-depth review. Nephron 1999; 83: 13.
3. Vanrenterghem Y, van Hooff JP, Squifflet JP, et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5(1): 87.
4. Opelz G, Dohler B, Laux G. Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5(4): 720.
5. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression - A 5-year experience. Am J Transplant 2005; 5(10): 2473.
6. ter Meulen CG, van Riemsdijk I, Hene RJ, et al. Steroid-withdrawal at 3 Days after renal transplantation with anti-IL-2 receptor therapy: A prospective, randomized, multicenter study. Am J Transplant 2004; 4(5): 803.
7. Artz MA, Boots JMM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4(6): 937.
8. Penson MG, Winter WE, Fricker FJ, et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999; 18(7): 707.
9. Kohnle M, Zimmermann U, Lutkes P, et al. Conversion from cyclosporine A to tacrolimus after kidney transplantation due to hyperlipidemia. Transpl Int 2000; Suppl 1: S345.
10. Fellström B. Risk factors for and management of post-transplantation cardiovascular disease. Bio Drugs 2001; 15(4): 261.
11. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67(7): 1036.
12. Kew CE, Curtis JJ. Cardiovascular disease in kidney transplant patients. Curr Opin Organ Transplant 1998; 3: 183.
13. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts: The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147(5): 645.
14. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
15. Kraemer BK, Montagnino G, del Castillo D, et al. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Nephrol Dial Transplant 2005; 20(5): 968.
16. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346(8): 580.
17. Ratcliffe PJ, Dudley CRK, Higgins RM, et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. Lancet 1996; 348: 643.
18. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62(1): 311.
19. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11(10): 1910.
20. Pascual J, Quereda C, Zamora J, Hernández D. Spanish Group for Evidence Based Medicine in Renal Transplantation. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78(10): 1548.